Armauer Hansen Research Institute

What Armauer Hansen Research Institute does

Armauer Hansen Research Institute (AHRI) is an Ethiopian research institution founded in 1970 and headquartered in Addis Ababa. Its mandate encompasses infectious disease research, clinical studies, diagnostic evaluation, and researcher training, positioning it as a longstanding pillar of Ethiopia's biomedical research infrastructure. The .gov.et domain indicates government affiliation, and its mandate aligns with Ethiopia's broader strategic objective of reducing pharmaceutical import dependence and building domestic regulatory and manufacturing capacity.

AHRI's externally visible activity centers on participation in international public health initiatives. In December 2025, it received over 640 doses of Sabin Vaccine Institute's investigational Marburg vaccine as part of Ethiopia's first Marburg virus disease outbreak response, executed within a U.S. government-supported Phase 2 clinical trial. AHRI is also associated with the World Bank Group-backed Kilinto Special Economic Zone, a dedicated hub supporting Ethiopia's shift from pharmaceutical imports to local manufacturing. The institute is classified as for-profit with 1-10 employees disclosed; the primary website (ahri.gov.et) was inaccessible during data collection, limiting visibility into detailed operational and financial metrics.

Business model mechanics are not publicly disclosed. As a government-affiliated research institute, AHRI most likely operates on a mix of public funding and donor-sponsored project grants rather than commercial revenue. No pricing, customer segmentation, product portfolio, or revenue figures were available in the source material. No management team, subsidiary structure, funding rounds, or M&A activity are documented.

Name

Armauer Hansen Research Institute

Website

https://ahri.gov.et

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

1–10 employees

Short description

Armauer Hansen Research Institute (AHRI) is an Ethiopian government-affiliated research institute founded in 1970 that conducts infectious disease research, clinical studies, diagnostic evaluation, and researcher training in Addis Ababa.

Ownership category

akta.pro rank

Product category

Public Health Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

General Infectious Disease (HLAKAGAA)

akta.pro secondary industries

Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), Infectious Disease Program Evaluation (e.g., HIV/TB/Malaria/STIs) (HLAJANAF)

Keywords

• Infectious disease research
• Clinical trial services
• Diagnostic evaluation
• Public health research
• Researcher training programs

Headquarters

HQ city

Addis Ababa

HQ country

Ethiopia

HQ region

Africa

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Core offering

Armauer Hansen Research Institute conducts infectious disease research, runs clinical studies, performs diagnostic evaluations, and delivers researcher training in Ethiopia. It functions as a national research body supporting public health priorities, with documented participation in outbreak response activities such as investigational vaccine trials.

Product overview

Based on the available source data, no specific product or service information was found for Armauer Hansen Research Institute. The primary website (ahri.gov.et) was inaccessible during data collection, displaying only a verification/loading page. The news sources provided context about Ethiopia's pharmaceutical regulatory achievements and vaccine delivery efforts, but did not contain details about Armauer Hansen Research Institute's specific product portfolio or service offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Infectious Disease Research
• Clinical Studies

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Sabin Vaccine InstitutecoreStrategic or Co-development Partner · 4 December 2025Sabin Vaccine Institute delivered over 640 doses of its investigational Marburg vaccine to Ethiopia for outbreak response. The vaccine is part of a Phase 2 clinical trial supported by the U.S. government. This partnership supports Ethiopia's first Marburg virus disease outbreak response with 13 cases and eight deaths reported.

Recent moves2 records

Expansion highlights3 records

Broad incumbents

• Pasteur Institute: Historic French biomedical research organization with a global network of Pasteur Institutes, several in Africa. A broad incumbent in the same infectious disease / vaccine science domain and a potential technical partner for AHRI.
• International Vaccine Institute (IVI): Seoul-headquartered international organization with a global vaccine R&D and clinical-trial footprint, including active programs in Africa. Functions as a broader incumbent funder/partner that AHRI can plug into for trial sponsorship.

Emerging players

• Sabin Vaccine Institute: Non-profit vaccine R&D organization that ran the Marburg vaccine trial in partnership with AHRI. A partner and emerging player in the same outbreak-response / vaccine-development ecosystem AHRI operates in.

Direct peers

• Ifakara Health Institute: Tanzania-based research institute focused on infectious disease, vector control, and health-systems research. Comparable in scale, mandate, and reliance on international donor funding for clinical and epidemiological studies in East Africa.
• Institut Pasteur de Dakar: A WHO-recognised vaccine manufacturer and infectious disease research center in West Africa. Shares AHRI's outbreak-response and clinical-trial profile and adds an African-based vaccine manufacturing angle aligned with Ethiopia's localization ambitions.
• Noguchi Memorial Institute for Medical Research: Ghana's leading public biomedical research institute with strong vaccine-trial and viral-diagnostics capacity. Directly comparable to AHRI in mandate (infectious disease research, clinical trials, training) and in being government-funded with international partnerships.
• Centre for Infectious Disease Research in Zambia (CIDRZ): Zambian public-health and infectious disease research organization running clinical trials and implementation science. Comparable to AHRI in running Phase 2/3 infectious disease trials supported by U.S. and European funders.
• Kenya Medical Research Institute (KEMRI): KEMRI is a long-established, government-affiliated infectious disease research institute in East Africa. Like AHRI, it conducts clinical trials, diagnostics, and outbreak response (including Ebola and cholera), making it the closest structural and geographic peer.
• Epicentre: MSF-affiliated epidemiology and clinical research organization operating in Africa on outbreak response and vaccine/diagnostic trials. Comparable mission and operating model to AHRI's infectious-disease research and outbreak activities.

Others

• Africa Centres for Disease Control and Prevention (Africa CDC): Continental public-health agency coordinating outbreak response and research across Africa. Functions as a regional convener/funding channel that AHRI increasingly depends on for outbreak-response mandates and trial coordination.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/AHRIGovEt
• LinkedInlinkedin.com/company/et.ahri

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Armauer Hansen Research Institute